Status:
COMPLETED
Once-A-Day Pregabalin For Partial Seizures
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Partial Seizures
Epilepsies, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dos...
Eligibility Criteria
Inclusion
- Diagnosis of epilepsy with partial onset seizures (seizures may be simple or complex, with or without evolution into a bilateral, convulsive seizure)
- Currently taking 1 to 3 anti-epilepsy medicines (AEDs) at stable dosages, and who have taken at least 2 prior (or ongoing) AEDs
Exclusion
- Primary generalized seizures (for example, absence, myoclonic seizures or Lennox-Gastaut Syndrome)
- Status epilepticus within one year prior to screening
Key Trial Info
Start Date :
February 17 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT01262677
Start Date
February 17 2011
End Date
August 1 2012
Last Update
January 25 2021
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology Clinic, PC
Northport, Alabama, United States, 35476
2
NEA Baptist Clinic
Jonesboro, Arkansas, United States, 72401
3
Clinical Trials, Inc.
Little Rock, Arkansas, United States, 72205
4
Collaborative Neuroscience Network, Inc.
Long Beach, California, United States, 90806